Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹596 Cr
P/E Ratio
40.11
P/B Ratio
2.15
Industry P/E
37.87
Debt to Equity
0.31
ROE
5.42 %
ROCE
7.42 %
Div. Yield
0 %
Book Value
126.17
EPS
6.83
CFO
₹170.90 Cr
EBITDA
₹198.97 Cr
Net Profit
₹77.97 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Sakar Healthcare
| -8.40 | 28.26 | -3.48 | -23.19 | 25.37 | 39.18 | -- |
|
BSE Healthcare
| -6.54 | 1.91 | 1.42 | 18.70 | 20.14 | 22.31 | 10.08 |
|
BSE Small Cap
| -13.49 | 1.63 | -3.38 | 0.28 | 18.33 | 33.99 | 15.77 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Sakar Healthcare
| -27.58 | 78.39 | 37.87 | 65.62 | 48.30 | 10.93 | -4.01 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 421.00 | 6,841.28 | 24.93 | 12.5 | |
| 5,082.00 | 8,400.95 | 35.51 | 43.77 | |
| 647.05 | 6,319.25 | 71.58 | 4.01 | |
| 649.90 | 6,082.74 | 22.57 | 12.68 |
Micro caps with a bullish sentiment
3 min read•By Danish Khanna and Udhayaprakash
Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. It provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable (SVP) in ampoules, vials... and lyophilized injections, and oral solid dosages. The company's product portfolio consists of formulations in approximately 22 therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins. It also exports its products to approximately 38 countries, including Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. The company was incorporated in 2004 and is based in Ahmedabad, India. Read more
Incorporated
2004
Chairman
Sanjay S Shah
Managing Director
Sanjay S Shah
Headquarters
Ahmedabad Dist, Gujarat
Website
Looking for more details about Sakar Healthcare Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Announcements
View Announcements
The total asset value of Sakar Healthcare Ltd stood at ₹ 404 Cr as on 31-Dec-24
The share price of Sakar Healthcare Ltd is ₹271.56 (NSE) as of 30-Apr-2025 IST. Sakar Healthcare Ltd has given a return of 25.37% in the last 3 years.
Sakar Healthcare Ltd has a market capitalisation of ₹ 596 Cr as on 30-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Sakar Healthcare Ltd is 2.15 times as on 30-Apr-2025, a 58% discount to its peers’ median range of 5.06 times.
The P/E ratio of Sakar Healthcare Ltd is 40.11 times as on 30-Apr-2025, a 6% premium to its peers’ median range of 37.87 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sakar Healthcare Ltd and enter the required number of quantities and click on buy to purchase the shares of Sakar Healthcare Ltd.
Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. It provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. The company's product portfolio consists of formulations in approximately 22 therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins. It also exports its products to approximately 38 countries, including Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. The company was incorporated in 2004 and is based in Ahmedabad, India.
The promoters of Sakar Healthcare Ltd are Sanjay S Shah and Shah Aarsh. They collectively own 52.01 per cent of the total equity. The chairman of the company is Sanjay S Shah
There is no promoter pledging in Sakar Healthcare Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
8,423
|
|
|
6,920
|
|
|
6,675
|
|
|
6,029
|
| Sakar Healthcare Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
5.61
|
|
Operating margin(%)
|
14.47
|
|
Net Margin(%)
|
8.63
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Sakar Healthcare Ltd was ₹15 Cr.
₹-19.81
(
